Rush to Buy Merck’s Covid Pill Risks Leaving Poor Countries Behind
Bloomberg - 10/12/2021
Then there are the hard-hit, middle-income countries that could get left out if licensing agreements favor lower-income nations, said Brook Baker, a professor at Northeastern University who warned of a new wave of “therapeutics nationalism.”
Then there are the hard-hit, middle-income countries that could get left out if licensing agreements favor lower-income nations, said Brook Baker, a professor at Northeastern University who warned of a new wave of “therapeutics nationalism.”